Highlights Crinetics Pharmaceuticals, Inc.

Equities

CRNX

US22663K1079

Market Closed - Nasdaq Other stock markets 01:30:00 14/05/2024 am IST			5-day change	1st Jan Change
47.93 ^USD	-0.15%		+3.08%	+34.71%

10/05	Crinetics Pharmaceuticals Insider Sold Shares Worth $5,307,931, According to a Recent SEC Filing	MT
09/05	Crinetics Pharmaceuticals Q1 Net Loss Widens	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Crinetics Pharmaceuticals Q1 Net Loss Widens	10/05	MT
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study	19/03	RE
Crinetics Pharmaceuticals, Inc. Announces Positive Topline Results from PATHFNDR-2, Second of Two Phase 3 Studies Evaluating Efficacy and Safety of Oral, Once-Daily Investigational Paltusotine for Treatment of Acromegaly	19/03	CI
Crinetics Pharmaceuticals Up in Extended Hours After Positive Top-Line Results for Drug Candidate	13/03	MT
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome	13/03	CI
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02	CI
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
Crinetics' Once-Daily Oral Paltusotine Achieves the Primary and All Secondary Endpoints in the Phase 3 Pathfr-1 Study Evaluating Treatment of Patients with Acromegaly	10/23/10	CI
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/23/08	CI
Crinetics Pharmaceuticals, Inc. Presents Efficacy, Safety and Patient-Reported Outcome Data At ENDO 2023	21/23/21	CI
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	05/23/05	CI
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	01/23/01	CI
Crinetics Pharmaceuticals, Inc. Provides Update on Crn04777 Program	28/22/28	CI
Crinetics Pharmaceuticals Q3 Loss Widens	14/22/14	MT
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
Crinetics Pharmaceuticals, Inc. Completes Enrollment in Phase 3 PATHFNDR-1 Study	13/22/13	CI
Crinetics Pharmaceuticals' CRN04777 Receives Innovation Passport in UK to Treat Congenital Hyperinsulinism	06/22/06	MT
Crinetics Pharmaceuticals, Inc Announces that Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism	06/22/06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Crinetics Pharmaceuticals, Inc.

Equities

CRNX

US22663K1079

Highlights

Filters